Hypertension Diagnostics, Inc. Signed LOI Merger Agreement with China Specialty International Limited

 Hypertension Diagnostics, Inc. (OTC: HDII) is pleased to announce that they have signed LOI Merger Agreement with China Specialty  (Hong Kong)  International Limited., It has more than 30 registered trademarks, and its business focuses on licensing, distribution authorization, investment in China. 

Mr. Bo Long, the Chairman of China Specialty (Hong Kong) International Limited noted that, “We are looking forward to taking the Company public on the OTC Markets in the U.S. We believe this will further our goals to continue expanding our business in China and Asian countries."

The two companies are looking forward to signing the final Merger Agreement. 

China Specialty (Hong Kong) International Limited 

Established in 2007, China Specialty (Hong Kong) International Limited is  incorporated under the laws of Hong Kong. China Specialty International Limited has more than 30 registered trademarks, and its business focuses on licensing, distribution authorization, investment, etc.

Hypertension Diagnostics, Inc.

Hypertension Diagnostics, Inc (OTC: HDII), is a public company currently trading on the OTC Markets (HDII). HDII was originally incorporated in MN.

*Safe Harbor Statement Information in this press release may contain ‘forward-looking statements.' Statements describing objectives or goals or the Company's future plans are also forward-looking statements and are subject to risks and uncertainties, including the financial performance of the Company and market valuations of its stock, which could cause actual results to differ materially from those anticipated. Forward-looking statements in this news release are made pursuant to the ‘Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to sales, acceptance of Hypertension Diagnostics, Inc’s products, increased levels of competition, changes, dependence on intellectual property rights and other risks detailed from time to time in Hypertension Diagnostics, Inc. periodic reports filed with the regulatory 

authorities.SOURCE: Hypertension Diagnostics, Inc

Investor Information: [email protected]